Home
|
Help
|
Contact
Sign in
WPRIM Management System>
DCMS
>
Clinical and Molecular Hepatology
>
2021
>
27
>
4
Volume:
27
Issue:
4
1. History and future of hepatitis B virus control in South Korea
Page:620—622
2. Can hepatocellular carcinoma recurrence be prevented after liver transplantation?
Page:562—563
3. Update on liver disease management during the pandemic of coronavirus disease 2019 (COVID-19): 2021 KASL guideline
Page:515—523
4. Impact of branched-chain amino acids and frailty on the management of lenvatinib-related fatigue in patients with hepatocellular carcinoma
Page:616—619
5. Cost-effectiveness and long-term outcomes of liver transplantation using hepatitis B core antibody-positive grafts with hepatitis B immunoglobulin prophylaxis in Korea
Page:603—615
6. Microwave thermosphere versus radiofrequency ablation for hepatocellular carcinoma: Are we approaching the time to end the debate?
Page:560—561
7. New next-generation microwave thermosphere ablation for small hepatocellular carcinoma
Page:564—574
8. Impact of everolimus on survival after liver transplantation for hepatocellular carcinoma
Page:589—602
9. Sofosbuvir/velpatasvir plus ribavirin for Child-Pugh B and Child-Pugh C hepatitis C virus-related cirrhosis
Page:575—588
10. Treatment of direct oral anticoagulants in patients with liver cirrhosis and portal vein thrombosis
Page:535—552
11. Recent advances in nonalcoholic fatty liver disease metabolomics
Page:553—559
12. Three heads are better than two: Hepatitis B core-related antigen as a new predictor of hepatitis B virus-related hepatocellular carcinoma
Page:524—534
13. History and future of hepatitis B virus control in South Korea
Page:620—622
14. Can hepatocellular carcinoma recurrence be prevented after liver transplantation?
Page:562—563
15. Update on liver disease management during the pandemic of coronavirus disease 2019 (COVID-19): 2021 KASL guideline
Page:515—523
16. Impact of branched-chain amino acids and frailty on the management of lenvatinib-related fatigue in patients with hepatocellular carcinoma
Page:616—619
17. Cost-effectiveness and long-term outcomes of liver transplantation using hepatitis B core antibody-positive grafts with hepatitis B immunoglobulin prophylaxis in Korea
Page:603—615
18. Microwave thermosphere versus radiofrequency ablation for hepatocellular carcinoma: Are we approaching the time to end the debate?
Page:560—561
19. New next-generation microwave thermosphere ablation for small hepatocellular carcinoma
Page:564—574
20. Impact of everolimus on survival after liver transplantation for hepatocellular carcinoma
Page:589—602
21. Sofosbuvir/velpatasvir plus ribavirin for Child-Pugh B and Child-Pugh C hepatitis C virus-related cirrhosis
Page:575—588
22. Treatment of direct oral anticoagulants in patients with liver cirrhosis and portal vein thrombosis
Page:535—552
23. Recent advances in nonalcoholic fatty liver disease metabolomics
Page:553—559
24. Three heads are better than two: Hepatitis B core-related antigen as a new predictor of hepatitis B virus-related hepatocellular carcinoma
Page:524—534